Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | LPO | P22079 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5826461 | 0.89 | NPY1R (0.50) | NPY1RMAPTTP53LMNAPOLB | |
| SCHEMBL5826672 | 0.89 | SLC2A1 (0.40) | NPY1RSLC2A1MAPTTP53LMNA | |
| Hydrochloric Acid SCHEMBL5826984 | 0.86 | NPY1R (0.39) | NPY1RMAPTTP53LMNAKDM4E | |
| SCHEMBL7492597 | 0.82 | NPY1R (0.39) | NPY1RMAPTLMNAKDM4EHTR6 | |
| Hydrochloric Acid SCHEMBL6209582 | 0.82 | MAPT (0.41) | NPY1RMAPTLMNAKDM4EPOLB | |
| SCHEMBL5826712 | 0.81 | MAPT (0.41) | NPY1RMAPTTP53KDM4ECMA1 | |
| SCHEMBL5826785 | 0.81 | NPY1R (0.38) | NPY1RMAPTPOLB | |
| SCHEMBL6496723 | 0.81 | NPY1R (0.38) | NPY1RMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5826943 | 0.81 | NPY1R (0.38) | NPY1RLMNAKDM4EHTR6SMN1; SMN2 | |
| SCHEMBL5830099 | 0.81 | NPY1R (0.41) | NPY1RMAPTTP53KDM4ECRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995163-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-6951865-B2 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| EP-1238979-B1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | NPY1R 101/4885LPO 4802/4885SLC2A1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.